Glaxo cuts drug prices for developing countriesBMJ 2001; 322 doi: https://doi.org/10.1136/bmj.322.7301.1510/a (Published 23 June 2001) Cite this as: BMJ 2001;322:1510
- Jacqui Wise
The pharmaceutical company GlaxoSmithKline is to lower the cost to the developing world of its antimalarial and newer HIV and AIDS drugs—a move welcomed by the World Health Organization (WHO) and aid charities.
GlaxoSmithKline set out its new policy in a document, Facing the Challenge. The newer HIV and AIDS drugs will join established treatments such as zidovudine (Retrovir), which is already available at preferential prices in developing countries.
Abacavir (Ziagen), a nucleoside analogue, will now cost £2.40 ($3.36) a day in developing countries, compared with a list price of £7.22 a day for the …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial